Display options
Cite
Bock C, Rack B, Kuhn C, et al. Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients. Transl Oncol. 2012;5(6):475-85doi: 10.1593/tlo.12310.
Bock, C., Rack, B., Kuhn, C., Hofmann, S., Finkenzeller, C., Jäger, B., Jeschke, U., & Doisneau-Sixou, S. F. (2012). Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients. Translational oncology, 5(6), 475-85. https://doi.org/10.1593/tlo.12310
Bock, Carolin, et al. "Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients." Translational oncology vol. 5,6 (2012): 475-85. doi: https://doi.org/10.1593/tlo.12310
Bock C, Rack B, Kuhn C, Hofmann S, Finkenzeller C, Jäger B, Jeschke U, Doisneau-Sixou SF. Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients. Transl Oncol. 2012 Dec;5(6):475-85. doi: 10.1593/tlo.12310. Epub 2012 Dec 01. PMID: 23323159; PMCID: PMC3542840.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2012 Dec;5(6):475-85. doi: 10.1593/tlo.12310. Epub 2012 Dec 01.

Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients.

Translational oncology

Carolin Bock, Brigitte Rack, Christina Kuhn, Simone Hofmann, Charlotte Finkenzeller, Bernadette Jäger, Udo Jeschke, Sophie F Doisneau-Sixou

Affiliations

  1. Tumorbiologisches Labor der Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany.

PMID: 23323159 PMCID: PMC3542840 DOI: 10.1593/tlo.12310

Abstract

Hormone therapy and anti-ErbB2 therapies are prescribed according to the hormone receptor [estrogen receptor α (ERα)/progesterone receptor] and ErbB2 status of the initial tumor, but it appears that circulating tumor cells (CTCs) and, consequently, the metastatic cells may have a different receptor status. As an attempt to meet the crucial need for identification of the subpopulation of patients that will benefit from more individualized therapies, rapidly evolving therapies should allow a profiling of the tumors and/or of the CTCs. We established a triple fluorescence staining using eight cell lines to visualize the CTCs (cytokeratin detection) and then to define their individual ERα and ErbB2 status. Afterward, we used this method for blood samples from 26 metastatic breast cancer patients. We identified major differences of ERα levels between the cell lines and even within one cell line. For the metastatic patients, we detected and characterized CTCs in 38.5% of the patients with a total of 92 CTCs. We could demonstrate that at least 69.6% of the CTCs exhibit an ERα and/or ErbB2 status different from the status of the primary tumor and that the CTCs from only 30% of the patients had no change of receptor status. Strikingly, heterogeneities of the status, aggregation, and size clearly appear within the CTCs. The data we generated outline the importance of a profiling not only of tumors but also of CTCs to establish individualized treatments. CTCs may then appear as new prognosis and treatment marker for both metastatic and adjuvant breast cancers.

References

  1. PLoS One. 2012;7(5):e33788 - PubMed
  2. Int J Cancer. 2011 Jul 15;129(2):417-23 - PubMed
  3. Ann Oncol. 2010 Jun;21(6):1254-1261 - PubMed
  4. Clin Cancer Res. 2010 Oct 15;16(20):5011-8 - PubMed
  5. Breast Cancer Res. 2011 Oct 25;13(5):222 - PubMed
  6. Eur J Cancer Prev. 2005 Dec;14(6):497-502 - PubMed
  7. J Cancer Res Clin Oncol. 2011 May;137(5):821-8 - PubMed
  8. Ann Oncol. 2012 Jul;23(7):1653-5 - PubMed
  9. J Clin Oncol. 2005 Mar 1;23(7):1420-30 - PubMed
  10. Breast Cancer Res Treat. 2011 Jul;128(1):155-63 - PubMed
  11. Cancer. 2003 Jan 15;97(2):405-11 - PubMed
  12. Cancer Metastasis Rev. 2012 Dec;31(3-4):663-71 - PubMed
  13. Br J Cancer. 2007 Feb 26;96(4):654-9 - PubMed
  14. Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18392-7 - PubMed
  15. Clin Cancer Res. 2012 Feb 15;18(4):993-1003 - PubMed
  16. N Engl J Med. 2004 Aug 19;351(8):781-91 - PubMed
  17. Breast Cancer Res Treat. 2009 Jun;115(3):581-90 - PubMed
  18. Nat Rev Cancer. 2009 Sep;9(9):631-43 - PubMed
  19. Anticancer Res. 2011 Feb;31(2):521-7 - PubMed
  20. Clin Cancer Res. 2010 May 1;16(9):2634-45 - PubMed
  21. Am J Clin Pathol. 2008 Dec;130(6):879-82 - PubMed
  22. J Histochem Cytochem. 2002 Apr;50(4):575-82 - PubMed
  23. Ann Oncol. 2009 Dec;20(12):1953-8 - PubMed
  24. Breast Cancer Res Treat. 2011 Aug;129(1):247-54 - PubMed
  25. Breast Cancer Res Treat. 2005 Mar;90(1):65-70 - PubMed
  26. Anticancer Res. 2009 Oct;29(10):4019-24 - PubMed
  27. Cancer. 2006 Sep 1;107(5):885-92 - PubMed
  28. J Hematol Oncol. 2008 May 28;1:2 - PubMed
  29. Nat Rev Drug Discov. 2012 Jun 01;11(6):479-97 - PubMed
  30. Recent Results Cancer Res. 2012;195:193-201 - PubMed
  31. Breast Cancer Res. 2008;10(5):R76 - PubMed
  32. Breast Cancer Res. 2009;11(4):R59 - PubMed
  33. Clin Cancer Res. 2006 Oct 1;12(19):5615-21 - PubMed
  34. Breast Cancer Res Treat. 2006 Jul;98(2):179-84 - PubMed
  35. Breast Cancer Res. 2000;2(6):400-7 - PubMed
  36. Cancer Treat Rev. 2012 May;38(3):226-34 - PubMed
  37. Expert Opin Ther Targets. 2011 Jan;15(1):21-30 - PubMed
  38. J Cell Biol. 2011 Feb 7;192(3):373-82 - PubMed
  39. Histol Histopathol. 2012 Jul;27(7):855-64 - PubMed
  40. J Cancer Res Clin Oncol. 2011 Sep;137(9):1317-27 - PubMed
  41. J Transl Med. 2012 Jul 02;10:138 - PubMed
  42. Breast Cancer Res Treat. 2010 Nov;124(2):403-12 - PubMed
  43. Breast Cancer Res. 2010;12(6):R92 - PubMed
  44. Sci Transl Med. 2010 Mar 31;2(25):25ra23 - PubMed
  45. PLoS One. 2011 Jan 10;6(1):e15624 - PubMed
  46. Cell Cycle. 2010 May 15;9(10):1918-28 - PubMed
  47. J Clin Oncol. 2011 Apr 20;29(12):1508-11 - PubMed
  48. Clin Cancer Res. 2010 Feb 15;16(4):1264-71 - PubMed
  49. Clin Breast Cancer. 2010 Oct 1;10(5):392-7 - PubMed
  50. BMC Med. 2011 Apr 21;9:43 - PubMed

Publication Types